Tranexamic Acid Clinical Research | Apply Online

Frequently Asked Questions (FAQs): Tranexamic Acid Clinical Research (W81XWH 12 CCCJPC TACR)

What is the title of this funding opportunity?

The funding opportunity is titled "Tranexamic Acid Clinical Research."

What is the Funding Opportunity Number (FON)?

The Funding Opportunity Number is W81XWH 12 CCCJPC TACR.

Who offered this grant opportunity?

This was a Department of Defense (DoD) funding opportunity. The awarding/associated agency was listed as the Department of the Army (USAMRAA), with broader oversight and award activity associated with the U.S. Army Medical Research and Materiel Command (USAMRMC).

What program was this solicitation part of?

The solicitation fell under the Combat Casualty Care Research Program, sponsored by the Assistant Secretary of Defense for Health Affairs through the Defense Health Program.

Which office managed and administered the opportunity?

Management and administration were tied to the Telemedicine and Advanced Technology Research Center (TATRC) at Fort Detrick, Maryland.

What was the main research focus?

The opportunity called for prospective clinical studies focused on the use of tranexamic acid (TXA) in patients suffering traumatic hemorrhage (traumatic bleeding).

What outcomes or questions was the DoD trying to address?

The stated goal was to generate clinically relevant evidence on how TXA affects outcomes in traumatic bleeding, emphasizing knowledge that can improve combat casualty care while also translating to civilian trauma systems.

What kinds of studies were being sought?

The DoD was looking for well-designed clinical research that evaluates TXA in real-world trauma care and produces findings clinicians, medical planners, and researchers can use to refine treatment decisions for severely bleeding patients.

Was this intended to be exploratory research, or closer to applied/operational impact?

The announcement positioned TXA clinical research as part of a larger biotechnology research effort expected to mature into outcomes or technologies suitable for advanced development activities within the DoD. In other words, projects were expected to be more than purely exploratory and to inform operational capability, clinical guidelines, or deployment-ready medical practice.

How much total funding was anticipated?

The DoD estimated a total program funding level of $12,000,000.

How many awards were anticipated?

Approximately four awards were anticipated.

What was the maximum award amount (award ceiling)?

The award ceiling was $4,000,000 per award.

Was there a minimum award amount (award floor)?

The award floor was listed as $0, meaning there was no specified minimum request amount. Actual award sizes would be driven by the project scope and merit.

What funding instrument(s) were used?

The funding instrument type included cooperative agreements and grants.

What is the practical difference between a cooperative agreement and a grant for this opportunity?

Based on the opportunity description, cooperative agreements can indicate substantial DoD involvement or collaboration during the project period, while grants are generally more traditional funding arrangements. The solicitation indicated that awards could take either form.

Was cost sharing or matching required?

No. There was no cost sharing or matching requirement.

Who was eligible to apply?

Eligibility was described as unrestricted, meaning it was broadly open to many applicant types, subject to any clarifications contained in the full announcement.

What types of organizations might "unrestricted eligibility" include?

The description indicates broad openness and gives examples such as universities, hospitals, nonprofits, companies, and other organizations, with the understanding that the full posting would contain any specific eligibility clarifications.

What activity category did this opportunity fall under?

It was classified under Science and Technology and other Research and Development.

What is the CFDA number associated with this program?

The CFDA number was 12.420 (Military Medical Research and Development).

When was the opportunity posted?

The opportunity was posted (and created) on November 2, 2012.

What was the application deadline?

The original and final closing date was January 28, 2013.

Is this opportunity still open?

No. It was archived on February 27, 2013, and the closing date was January 28, 2013.

Where were applicants directed if they had trouble accessing the full announcement?

Applicants were directed to contact the named grants officer, Mary Rico, for issues accessing the full announcement electronically.

Where would the detailed submission requirements and study expectations have been found?

The description notes that detailed submission requirements, study expectations, and any special eligibility or protocol considerations would have been contained in the complete posting/full announcement.

Why was the DoD interested in TXA research specifically in trauma?

The opportunity framed TXA clinical research as a targeted investment in trauma medicine to strengthen the evidence base for TXA use in traumatic hemorrhage and deliver results relevant to both battlefield care and civilian emergency/trauma systems.

What was the intended end-user value of the research results?

The DoD emphasized producing findings that matter for clinicians, medical planners, and researchers, with the intent to refine treatment decisions for severely bleeding patients and improve trauma care practices.

What geographic location was mentioned in connection with administration?

TATRC at Fort Detrick, Maryland, was identified in connection with management and administration.